Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia
NCT ID: NCT06361407
Last Updated: 2024-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
68 participants
INTERVENTIONAL
2024-09-01
2028-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Links Between Perception of Temporal Order Judgment and Causality in Schizophrenia
NCT03432000
EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia
NCT05296720
Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia
NCT02896374
Visual Information Processing in Schizophrenia Patients With Visual Hallucinations
NCT03188133
Perceptual Deficits in Schizophrenia
NCT02337439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Perturbations will be introduced during the trajectory in the illusion task with and without rebound to test this hypothesis (acceleration on a millisecond scale vs. uniform speed). Patients suffering from schizophrenia, whose prediction mechanisms are fragile, are expected to be abnormally sensitive to trajectory changes. The experimental manipulations will help to compare sensory prediction (illusion without rebound) and top-down (conscious) prediction (illusion with rebound).
The protocol will also help to specify which types of prediction (sensory or cognitive) underlie patients' sense patients' sense of self. In short, the protocol is designed to improve the pathophysiological understanding of sense-of-self disorders in schizophrenia
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
effect of trajectory perturbation
All participants will run the task consisting in 2 squares moving towards each other. On each trial they will answer whether the squares touch or do not touch. All participants are tested with all experimental conditions. The rate of 'touch' responses will be compared when there is a trajectory perturbation without rebound vs. a trajectory with perturbation with rebound vs. a trajectory without perturbation and without rebound vs. a trajectory without perturbation and with rebound.
Illusion task
The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Illusion task
The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 60 inclusive;
* Subject having dated and signed the consent form prior to the start of any trial-related procedure (guardian or curator where applicable);
* Member of a social security scheme or beneficiary of such a scheme.
Exclusion Criteria
* Use of benzodiazepines, hallucinogens (in the period preceding before inclusion, for a duration equivalent to 5 half-lives of the product) or cannabis (in the 2 months preceding inclusion);
* Neurological pathology or sequelae;
* Attention deficit hyperactivity disorder (ADHD);
* Borderline personality disorder;
* Disabling sensory disorders (visual acuity \<0.8);
* Person deprived of liberty or under court protection;
* Pregnant, parturient or breast-feeding women;
* Subjects in a period of exclusion defined by another clinical study.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Centre Psychothérapique de Nancy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Giersch, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A02464-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.